What is the recommended approach to diagnosing and treating polycythemia, including workup for primary versus secondary causes and appropriate management strategies?

Approach to Polycythemia

Initial Diagnostic Strategy

Begin by measuring hemoglobin/hematocrit and determining if polycythemia is isolated or accompanied by other cytopenias (leukocytosis, thrombocytosis, splenomegaly), as this fundamentally directs your diagnostic pathway.

If Polycythemia is Isolated (No Leukocytosis/Thrombocytosis/Splenomegaly)

Prioritize excluding secondary causes first 1:

• Check for chronic hypoxia: Sleep apnea, chronic lung disease, high altitude residence, smoking history
• Medication review: SGLT2 inhibitors, androgens, erythropoietin-stimulating agents
• Assess for relative polycythemia: Chronic dehydration, diuretic use, plasma volume contraction
• Screen for erythropoietin-secreting tumors: Renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma

If secondary causes are excluded, then proceed to JAK2 mutation testing and serum erythropoietin levels 1.

If Polycythemia is Accompanied by Leukocytosis, Thrombocytosis, or Splenomegaly

Immediately test for JAK2 mutations and serum erythropoietin levels, as polycythemia vera (PV) is the likely diagnosis 1, 2.

Diagnostic Criteria for Polycythemia Vera

The diagnosis of PV requires both major criteria plus 1 minor criterion, OR the first major criterion plus 2 minor criteria 3:

Major Criteria:

1. Hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women (or hemoglobin increase >2 g/dL from baseline, or hematocrit >99th percentile for age/sex) 3
2. Presence of JAK2V617F or JAK2 exon 12 mutation 3

Minor Criteria:

1. Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) 3
2. Serum erythropoietin level below normal reference range 3
3. Endogenous erythroid colony formation in vitro 3

Critical caveat: Iron deficiency lowers hemoglobin and can mask PV. In clinical practice, you can make a working diagnosis of PV despite not meeting hemoglobin thresholds if iron deficient, but for research purposes, iron replacement is required before formal diagnosis 3.

Bone marrow biopsy is essential for accurate diagnosis and baseline histomorphology, particularly to distinguish PV from other JAK2V617F-positive myeloproliferative neoplasms 4, 5. The 2018 ELN guidelines recommend lower hemoglobin/hematocrit thresholds and emphasize bone marrow examination 4.

Risk Stratification

Stratify all PV patients into risk categories based on thrombosis risk 6, 7:

• High risk: Age ≥60 years OR prior thrombosis history
• Low risk: Age <60 years AND no thrombosis history

Treatment Approach

All Patients (Universal Therapy)

Every PV patient requires phlebotomy to maintain hematocrit <45% and once-daily low-dose aspirin (unless contraindicated) 6, 7. The hematocrit target of <45% is critical for reducing thrombosis risk.

High-Risk Patients or Symptomatic Low-Risk Patients

Add cytoreductive therapy 4, 6, 7:

First-line cytoreductive options:

• Hydroxyurea: Standard first-line agent with long-term safety track record and evidence for thrombosis reduction 6, 7
• Pegylated interferon-alpha: Preferred alternative in specific situations 4, 6:
  • Young women of reproductive age
  • Intolerance or resistance to hydroxyurea
  • When treatment goal is reducing phlebotomy requirement rather than preventing thrombosis
  • Evidence suggests improved survival outcomes 5

Second-line options for hydroxyurea-intolerant or inadequate responders:

• Ruxolitinib (JAK1/JAK2 inhibitor): Recommended for patients with protracted pruritus or symptoms resembling post-PV myelofibrosis 4, 6
• Busulfan: Preferred in older patients 6

Monitoring Strategy

• Initial phase: Monthly visits until blood counts normalize and splenomegaly resolves 2
• Maintenance phase: Every 2 months with complete blood count, blood smear evaluation, and clinical assessment 2
• Repeat bone marrow biopsy: Only if clinical signs suggest disease evolution (myelofibrosis or leukemic transformation) 2

Key Clinical Pitfalls

1. Missing iron deficiency: Always check iron studies, as iron deficiency masks elevated hemoglobin and delays diagnosis 3
2. Failing to exclude secondary causes in isolated polycythemia: This prevents unnecessary genetic testing and focuses care appropriately 1
3. Inadequate hematocrit control: Both phlebotomy AND cytoreductive agents may be needed; phlebotomy alone is often inadequate long-term 5
4. Overlooking unusual thrombosis sites: PV causes splanchnic vein thrombosis in 7% of patients 7
5. Extreme thrombocytosis (≥1000 × 10⁹/L): Paradoxically increases bleeding risk due to acquired von Willebrand disease; avoid aspirin in this setting 7

Prognosis and Complications

Median survival ranges from 14-28 years, with younger patients (age <60) achieving >35 years 6, 7. Twenty-year complication rates include:

• Thrombosis: 26%
• Myelofibrosis: 12.7-16%
• Acute myeloid leukemia: 4-6.8%

Current treatments reduce thrombosis risk but have not been proven to prevent fibrotic or leukemic transformation or prolong survival 6.